News

University of Illinois at Chicago investigators compared virologic failure among MSM and transgender women receiving HIV care at a community-based model with those receiving care at a hospital-based model.

In the absence of interpretive criteria, Fosfomycin has been used to treat Psuedomonas aeruginosa infections, but new research suggests that this option should be evaluated further.

The Closing Plenary of IDWeek 2019 discussed the challenges of vaccination and the optimism that we may be on the path to eradicating some global infectious diseases.

Millennials are a major population affected by the opioid crisis, which has now translated to an increase in hepatitis C virus infections among the generation.

Long-term care facilities participating in a statewide initiative in Nebraska saw improvements in antimicrobial stewardship, including drops in antibiotic starts and C diff infections.

The announcement came just 1 day after health officials in New York State declared the end of the Rockland County measles outbreak.

In the first study of its kind, investigators found ceftolozane/tazobactam is more effective than the most common therapy for multidrug-resistant P aeruginosa.

For individuals living with HIV, switching suppressive HIV regimens may be considered for a variety of reasons including treatment simplification, improved safety and tolerability, drug-drug interactions, or cost.

ART-related medication errors can occur and lead to suboptimal therapy and in some cases treatment resistance.

In general, women shared many of the same positive perceptions of long-acting ART that men did but offered unique insight.

Switching from TDF to TAF was associated with a 13% increase in the expected mean for ASCVD risk score (95% CI: 4%, 23%).

The study investigators conclude that U=U awareness seems to be improving among GBMSM, with HIV-negative individuals making the most progress.

A team of investigators set out to evaluate if administering CMV HIG to women with primary CMV infection during pregnancy could reduce congenital infections.

In a late-breaking presentation at IDWeek 2019, investigators from Israel sought to evaluate the effect of the antiviral drug valacyclovir on the rate of vertical transmission of CMV.

The mobile unit provided services to 229 clients from October 2018 to April 2019, 168 (73.7%) of whom sought PrEP.

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of September 29, 2019.

Machine learning prediction accuracies ranged from 75.6% (P aeruginosa and ceftazidime; 90/119 correctly predicted) to 98.1% (P aeruginosa and amikacin; 105/107 correctly predicted).

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

In results presented at IDWeek2019, investigators demonstrated a distinct “signature” of AFM in blinded cerebrospinal fluid samples >80% of the time.

The risk of incident DM was more substantial with INSTIs vs. NNRTIs (HR=1.22; CI: 0.95-1.57), and a similar rate was noted with PI- vs. NNRTI-initiators (HR=1.25; CI: 1.05-1.49).

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of IDWeek 2019 to date.

A new study demonstrated a high prevalence of ESBL among Klebsiella isolates mainly from fish effluents and diarrheal stool samples. Overall, there was an ESBL positive rate of 24%.

A 7-year study highlights the ability of an ultra-long-acting injectable implant to elute HIV drug combinations for months at a time.

In order to overcome the barriers to HIV care, it is important for both patients and health care professionals to mutually agree that a particular strategy is useful.

Two late breaker abstracts at IDWeek 2019 provide an in-depth analysis of the 2018-19 measles outbreaks in the state of New York.

While hospital-onset SAB accounted for about 1 in 10 cases, it is associated with 182% higher complication rate and 144% higher mortality than community-onset infections.

The most common presentation for pediatric invasive aspergillosis patients was a pulmonary infection.

RBX2660, a microbiota-based drug, was safe and efficacious for preventing recurrent C diff infection with clinical durability to 24-months after treatment, independent of age or sex.